Search hospitals > Alaska > Anchorage
Alaska Oncology and Hematology LLC
Claim this profileAnchorage, Alaska 99508
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
210 reported clinical trials
8 medical researchers
Summary
Alaska Oncology and Hematology LLC is a medical facility located in Anchorage, Alaska. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Alaska Oncology and Hematology LLC is involved with conducting 210 clinical trials across 410 conditions. There are 8 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Alison K. ConlinProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
99 reported clinical trials
175 drugs studied
Charles W. DrescherProvidence Portland Medical Center1 year of reported clinical research
Expert in Cancer
Studies Tumors
44 reported clinical trials
85 drugs studied
Nitya AlluriProvidence Portland Medical Center1 year of reported clinical research
Expert in Cancer
Studies Recurrence
28 reported clinical trials
79 drugs studied
Krishna C. AlluriProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Studies Adenocarcinoma
26 reported clinical trials
63 drugs studied
Clinical Trials running at Alaska Oncology and Hematology LLC
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Bladder Cancer
Bladder Carcinoma
Multiple Myeloma
Pancreatic Cancer
Gastric Cancer
Prostate Cancer
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Alaska Oncology and Hematology LLC?
Alaska Oncology and Hematology LLC is a medical facility located in Anchorage, Alaska. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Alaska Oncology and Hematology LLC is involved with conducting 210 clinical trials across 410 conditions. There are 8 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.